Patents by Inventor John J. Nemunaitis
John J. Nemunaitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10253331Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: August 29, 2017Date of Patent: April 9, 2019Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20180073038Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: ApplicationFiled: August 29, 2017Publication date: March 15, 2018Inventors: John J. NEMUNAITIS, Neil SENZER, Phillip B. MAPLES, Donald RAO
-
Patent number: 9914977Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding sType: GrantFiled: June 3, 2016Date of Patent: March 13, 2018Assignee: GRADALIS, INC.Inventors: David M. Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9790518Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically, the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to segment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: July 31, 2015Date of Patent: October 17, 2017Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9695422Abstract: Compositions and methods to attenuate the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: September 3, 2015Date of Patent: July 4, 2017Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20170175124Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.Type: ApplicationFiled: December 21, 2016Publication date: June 22, 2017Inventors: David M. Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20170073768Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding sType: ApplicationFiled: June 3, 2016Publication date: March 16, 2017Inventors: David M. Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9528991Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.Type: GrantFiled: November 7, 2014Date of Patent: December 27, 2016Assignee: GRADALIS, INC.Inventors: David M. Shanahan, John J. Nemunaitis, I, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20160333351Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.Type: ApplicationFiled: April 28, 2016Publication date: November 17, 2016Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neil Senzer
-
Patent number: 9382589Abstract: In certain preferred embodiments, the invention provides methods for treating cancer, which comprise (a) obtaining a specimen of cancer tissue from a patient; (b) obtaining a specimen of normal tissue in the proximity of the cancer tissue from such patient; (c) extracting total protein and RNA from the cancer tissue and normal tissue; (d) obtaining a protein expression profile of the cancer tissue and normal tissue using 2D DIGE and mass spectrometry; (e) identifying proteins that are expressed in such cancer tissue at significantly different levels than in the normal tissue; (f) obtaining a gene expression profile of the cancer tissue and normal tissue using microarray technology and comparing the results thereof to the protein expression profile; (g) prioritizing over-expressed proteins by assessing the connectivity thereof to other cancer-related or stimulatory proteins; (h) designing an appropriate RNA interference expression cassette to, directly or indirectly, modulate the expression of genes encoding sType: GrantFiled: November 4, 2013Date of Patent: July 5, 2016Assignee: GRADALIS, INC.Inventors: David Shanahan, John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20160175461Abstract: According to certain embodiments of the present invention, methods for modulating the production of sialic acid in a system are provided, which comprise providing the system with a wild-type GNE-encoding nucleic acid sequence. According to such embodiments, the system may comprise a cell, muscular tissue, or other desirable targets. Similarly, the present invention encompasses methods for producing wild-type GNE in a system that comprises a mutated endogenous GNE-encoding sequence. In other words, the present invention includes providing, for example, a cell or muscular tissue that harbors a mutated (defective) GNE-encoding sequence with a functional wild-type GNE encoding sequence.Type: ApplicationFiled: February 29, 2016Publication date: June 23, 2016Inventors: Phillip B. Maples, Chris M. Jay, John J. Nemunaitis
-
Patent number: 9353373Abstract: The present invention includes compositions and methods for making and using a bifunctional shRNAs capable of reducing an expression of a K-ras gene, e.g., a mutated K-ras gene, wherein at least one target site sequence of the bifunctional RNA molecule is located within the K-ras gene and wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of K-ras.Type: GrantFiled: May 9, 2013Date of Patent: May 31, 2016Assignee: STRIKE BIO, INC.Inventors: Donald Rao, Zhaohui Wang, John J. Nemunaitis, Neal Senzer
-
Patent number: 9273300Abstract: According to certain embodiments of the present invention, methods for modulating the production of sialic acid in a system are provided, which comprise providing the system with a wild-type GNE-encoding nucleic acid sequence. According to such embodiments, the system may comprise a cell, muscular tissue, or other desirable targets. Similarly, the present invention encompasses methods for producing wild-type GNE in a system that comprises a mutated endogenous GNE-encoding sequence. In other words, the present invention includes providing, for example, a cell or muscular tissue that harbors a mutated (defective) GNE-encoding sequence with a functional wild-type GNE encoding sequence.Type: GrantFiled: February 7, 2008Date of Patent: March 1, 2016Assignee: STRIKE BIO, INCInventors: Phillip Maples, Chris Jay, John J. Nemunaitis
-
Publication number: 20150368651Abstract: Compositions and methods to attenuate the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs is described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: ApplicationFiled: September 3, 2015Publication date: December 24, 2015Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Publication number: 20150329873Abstract: Compositions and methods for cancer treatment are disclosed herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: ApplicationFiled: July 31, 2015Publication date: November 19, 2015Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9157084Abstract: Compositions and methods to attenuate the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs was substituted therefor described herein. The bi-functional shRNAs of the present invention knocks down the expression of furin in cancer cells to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: December 20, 2010Date of Patent: October 13, 2015Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9132146Abstract: Compositions and methods for cancer treatment are discloses herein. More specifically the present invention describes an autologous cancer vaccine genetically modified for Furin knockdown and GM-CSF expression. The vaccine described herein attenuates the immunosuppressive activity of TGF-? through the use of bi-functional shRNAs to knock down the expression of furin in cancer cells, and to augment tumor antigen expression, presentation, and processing through expression of the GM-CSF transgene.Type: GrantFiled: December 20, 2010Date of Patent: September 15, 2015Assignee: GRADALIS, INC.Inventors: John J. Nemunaitis, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 9133459Abstract: A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene.Type: GrantFiled: December 4, 2012Date of Patent: September 15, 2015Assignees: Strike Bio, Inc., Baylor College of MedicineInventors: John J. Nemunaitis, Donald Rao, F. Charles Brunicardi
-
Publication number: 20150086619Abstract: In certain embodiments, the invention provides methods for treating cancer, comprising: obtaining a specimen of cancer tissue and normal tissue from a patient; extracting total protein; obtaining a protein expression profile; identifying over-expressed proteins; comparing the protein expression profile to a gene expression profile; identifying at least one prioritized protein target; designing a first RNA interference expression cassette; designing a first RNA interference expression cassette to modulate the expression of at least one gene encoding; incorporating the first cassette into a delivery vehicle; and providing a patient with an effective amount of the first delivery vehicle.Type: ApplicationFiled: November 7, 2014Publication date: March 26, 2015Inventors: David M. Shanahan, John J. Nemunaitis, I, Neil Senzer, Phillip B. Maples, Donald Rao
-
Patent number: 8906874Abstract: The present invention includes bifunctional shRNAs capable of reducing an expression of a Stathmin 1 gene; wherein at least one target site sequence of the bifunctional RNA molecule is located within the Stathmin 1 gene, wherein the bifunctional RNA molecule is capable of activating a cleavage-dependent and a cleavage-independent RNA-induced silencing complex for reducing the expression level of Stathmin 1.Type: GrantFiled: March 1, 2012Date of Patent: December 9, 2014Assignee: Gradalis, Inc.Inventors: Donald Rao, John J. Nemunaitis, Neil Senzer